Other research analysts also recently issued reports about the stock. Commerzbank AG reissued a buy rating on shares of Qiagen NV in a research report on Friday, September 9th. Zacks Investment Research raised shares of Qiagen NV from a hold rating to a buy rating and set a $29.00 price objective on the stock in a research report on Wednesday, September 14th. Morgan Stanley set a $30.00 price objective on shares of Qiagen NV and gave the stock a buy rating in a research report on Sunday, September 11th. TheStreet raised shares of Qiagen NV from a hold rating to a buy rating in a research report on Friday, July 29th. Finally, Mizuho raised their price objective on shares of Qiagen NV from $22.00 to $25.00 and gave the stock a neutral rating in a research report on Monday, August 1st. Seven equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. The stock presently has an average rating of Buy and a consensus price target of $25.36.
Qiagen NV (NASDAQ:QGEN) opened at 26.87 on Monday. The firm has a market cap of $6.29 billion, a P/E ratio of 53.74 and a beta of 0.90. Qiagen NV has a 52-week low of $19.94 and a 52-week high of $28.04. The company’s 50 day moving average is $26.76 and its 200 day moving average is $23.39.
Qiagen NV (NASDAQ:QGEN) last posted its earnings results on Thursday, July 28th. The company reported $0.24 EPS for the quarter, beating the Zacks’ consensus estimate of $0.23 by $0.01. The firm had revenue of $334.40 million for the quarter, compared to the consensus estimate of $326.73 million. Qiagen NV had a net margin of 9.13% and a return on equity of 9.21%. The company’s revenue was up 4.7% on a year-over-year basis. During the same period last year, the firm posted $0.26 EPS. Equities research analysts forecast that Qiagen NV will post $1.09 EPS for the current fiscal year.
Several hedge funds have recently made changes to their positions in the stock. Goldman Sachs Group Inc. boosted its stake in shares of Qiagen NV by 59.4% in the first quarter. Goldman Sachs Group Inc. now owns 1,448,832 shares of the company’s stock valued at $32,366,000 after buying an additional 539,870 shares during the period. Douglas Lane & Associates LLC boosted its position in shares of Qiagen NV by 1.1% in the second quarter. Douglas Lane & Associates LLC now owns 1,942,678 shares of the company’s stock worth $42,370,000 after buying an additional 21,675 shares during the last quarter. State Street Corp boosted its position in shares of Qiagen NV by 3.0% in the first quarter. State Street Corp now owns 2,094,136 shares of the company’s stock worth $46,785,000 after buying an additional 61,463 shares during the last quarter. State Board of Administration of Florida Retirement System boosted its position in shares of Qiagen NV by 13.9% in the second quarter. State Board of Administration of Florida Retirement System now owns 332,877 shares of the company’s stock worth $7,260,000 after buying an additional 40,727 shares during the last quarter. Finally, HBK Investments L P acquired a new position in shares of Qiagen NV during the first quarter worth about $344,000. Hedge funds and other institutional investors own 58.76% of the company’s stock.
About Qiagen NV
QIAGEN N.V. (QIAGEN) is a holding company. The Company and its subsidiaries are engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Sample to Insight solutions are composed of sample and assay technologies, bioinformatics and automation systems.
Receive News & Ratings for Qiagen NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen NV and related companies with MarketBeat.com's FREE daily email newsletter.